Head-to-head evidence
GPC-100 vs Plerixafor
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Myeloma
Shared mechanism: CXCR4 · full Multiple Myeloma pipeline
GPC-100
Developed by GPCR Therapeutics, Inc.
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Plerixafor
Marketed by Sanofi
NCT00103662 · Phase 3 · completed
This was a randomized, quadruple-blinded, placebo-controlled Phase 3 trial with a reasonably large sample (302 patients) and a clinically meaningful primary endpoint (achieving a target stem cell yield within a defined apheresis window). Results were not posted at the time of grading; the key result shown was recorded subsequently from the registry record.
Next expected readout: December 2027 · NCT07188090 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: GPC-100's landscape · Plerixafor's landscape